STUDY SEARCH RESULTS

1 study found for your search request:  4280-003

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizuma...
Condition: Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT03598608
Status: Active, not recruiting




Copyright © 2025 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site